AMRZ vs KGC

The company exhibits a Piotroski F-Score of 4/9, indicating stable but not robust financial health, while the absence of an Altman Z-Score limits distress risk assessment. Valuation metrics suggest the stock trades at a premium to both the Graham Number ($35.19) and intrinsic value ($16.52), supported by a high P/E of 22.98 versus sector peers. Despite solid operating margins and manageable leverage, earnings growth is negative year-over-year and quarterly earnings surprises have been inconsistent. Analysts recommend a 'buy' with a target price of $60.08, implying upside, but weak recent price performance and lack of dividend or insider activity temper near-term conviction.

KGC presents a stable deterministic health profile with a Piotroski F-Score of 4/9 and a defensive Graham Number of $17.71, though it is currently trading at a premium to this defensive floor. However, the growth-based Intrinsic Value of $57.52 and explosive earnings growth (237.9% YoY) suggest the market is pricing in significant expansion. The company's financial health is exceptional, characterized by negligible debt (Debt/Equity 0.09) and high profitability (ROE 31.48%). Despite a bearish technical trend, the fundamental trajectory and consistent earnings beats support a strong bullish outlook.